dc.creator | Đorđević, J. | |
dc.creator | Mitrović, M. | |
dc.creator | Marinković, Valentina | |
dc.creator | Tasić, Ljiljana | |
dc.creator | Krajnović, Dušanka | |
dc.date.accessioned | 2019-09-02T11:39:15Z | |
dc.date.available | 2019-09-02T11:39:15Z | |
dc.date.issued | 2014 | |
dc.identifier.issn | 1098-3015 | |
dc.identifier.uri | https://farfar.pharmacy.bg.ac.rs/handle/123456789/2109 | |
dc.description.abstract | Objectives: Colistimethate sodium (Colistin) is an old, “forgotten” antibiotics
revived due to multidrug-resistant Gram-negative bacteria in nosocomial infec-
tions. In many countries, both – intravenous and inhalational administrations of
Colistin have marketing authorisation. In Serbia, Colistin is registered only for
intravenous administration. Therefore, inhalational administration of Colistin in
treatment for cystic fibrosis is considered as off label use. AiM: The purpose of
this study was to assess benefits of Colistin off label use, currently available in
Serbia, for treatment for cystic fibrosis. MethOds: Data collected from a review
of the literature (Pubmed searching key word off label, Colistin, Tobramycine, cost
minimisation) and data from Health Insurance Fond of Republic Serbia (2014)
were used to perform a cost-minimisation analysis comparing DDD in inhalation
administration of Colistin with Tobramycin (official methodology in Serbia for drug
reimbursement Listing). Results: Both, Colistin and Tobramycine are effective
in cystic fibrosis treatment. The cost of treatment per patient per year in Serbia is
3 616,00 Euro for Colistin and 5 950,00 Euro for Tobramycin. Total savings per year
for 200 registered patients in Serbia could be 466 857,00 Euro. cOnclusiOns:
Given cost-minimisation analysis justified the treatment with Colistin as cost
saving therapeutic alternative to Tobramycin for cystic fibrosis patients in Serbia.
The lack of guidelines and principles regarding off label medicine use in health
care policy and decision making in Serbia was evidently an obstacle for better
patients care. | |
dc.publisher | Elsevier Science Inc | |
dc.rights | openAccess | |
dc.source | Value in Health | |
dc.title | Cost-Minimisation Analysis of Colistimethate Sodium in Serbia- off Label Use Approach | en |
dc.type | conferenceObject | |
dc.rights.license | ARR | |
dcterms.abstract | Тасић, Љиљана; Митровић, М.; Ђорђевић, Ј.; Крајновић, Душанка; Маринковић, Валентина; | |
dc.citation.volume | 17 | |
dc.citation.issue | 7 | |
dc.citation.spage | A399 | |
dc.citation.epage | A399 | |
dc.citation.other | 17(7): - | |
dc.citation.rank | aM21 | |
dc.identifier.wos | 000346917300420 | |
dc.identifier.doi | 10.1016/j.jval.2014.08.904 | |
dc.identifier.pmid | 27200947 | |
dc.identifier.fulltext | http://farfar.pharmacy.bg.ac.rs/bitstream/id/10613/Cost_Minimisation_Analysis_pub_2014.pdf | |
dc.type.version | publishedVersion | |